New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
11:25 EDTBPTHBio-Path Holdings announces Liposomal Grb-2 Phase 1 data presented
Bio-Path Holdings announced the presentation of Phase I data from Bio-Path’s clinical trial evaluating its lead product candidate, Liposomal Grb-2 in hematological cancers. The study was included in the first five cohorts of the study. The sixth cohort of the study is ongoing, and Bio-Path expects to have enrollment completed in 1Q14. The clinical trial was a standard dose-finding study. The starting dose was 5 mg/m2 twice weekly intravenously over two to three hours for 28 days and proceeded through doses of 10, 20, 40, and 60 mg/m2. A total of 28 patients who had failed other therapies were included in the study and 18 patients were evaluable. Preliminary results suggest that BP-100-1.01 at doses up to 60 mg/m2 is well tolerated and there is suggestion of anti-leukemia activity. Of the evaluable patients, all showed a transient drop in circulating or bone marrow blast percentage. Doses administered in Cohorts 1-5 expected to be below Optimal Biological Dose. As the study progresses it is anticipated that clearer signs of activity will be noted.
News For BPTH From The Last 14 Days
Check below for free stories on BPTH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BPTH

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use